翰森制药：阿美乐 (甲磺酸阿美替尼片)第五项适应症获国家药品监督管理局签发药品注册证书

Core Viewpoint - Hansoh Pharmaceutical (03692) announced that its innovative drug Amelot (Ametinib Mesylate Tablets) has received a drug registration certificate from the National Medical Products Administration (NMPA) in China, approving the addition of a new indication for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. This marks the fifth approved indication for Amelot [1]. Group 1 - Hansoh Pharmaceutical's Amelot has received approval for a new indication in NSCLC treatment [1] - The new indication involves the combination of Amelot with pemetrexed and platinum-based chemotherapy [1] - This approval represents the fifth indication for the drug, highlighting its expanding therapeutic potential [1]